Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander C Conley

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Digital Health|August 17, 2023
Use of focused computerized cognitive training (Neuroflex) to improve symptoms in women with persistent chemotherapy-related cognitive impairmentJennifer N Vega, Paul A Newhouse, Alexander C Conley, et al.
Menopause (New York, N.Y.)|October 28, 2020
Cognitive complaints are associated with smaller right medial temporal gray-matter volume in younger postmenopausal womenAlexander C Conley, Kimberly M Albert, Brian D Boyd, et al.
Research Square|April 16, 2025
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of the Muscarinic M 1 Positive Allosteric Modulator VU0467319 for Alzheimer's disease: A Single Ascending-Dose Study in Healthy ParticipantsAlexander C Conley, Alexandra P Key, Jennifer U Blackford, et al.
Alzheimer'S Research & Therapy|July 2, 2025
Safety, tolerability, pharmacokinetic and pharmacodynamic effects of the muscarinic M<sub>1</sub> positive allosteric modulator VU0467319 for Alzheimer's disease: a single ascending-dose study in healthy participantsAlexander C Conley, Alexandra P Key, Jennifer U Blackford, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 7, 2025
Brain cholinergic terminal density utilizing [<sup>18</sup>F]-fluoroethoxybenzovesamicol PET in adults with Down's syndrome: Relationship to amyloid PET and cognitive performanceJason K Russell, Alexander C Conley, Brian D Boyd, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 24, 2025
BiomarkersJason K Russell, Alexander C Conley, Brian Boyd, et al.
Neurobiology of Aging|February 6, 2025
Differences in cholinergic terminal density in adults with Down syndrome compared to neurotypical controls measured by [<sup>18</sup>F]-fluoroethoxybenzovesamicol positron emission tomography imagingJason K Russell, Alexander C Conley, Brian D Boyd, et al.
Medrxiv : the Preprint Server for Health Sciences|November 22, 2024
Age-Related Changes in the Cholinergic System in Adults with Down Syndrome Assessed Using [<sup>18</sup>F]-Fluoroethoxybenzovesamicol Positron Emission Tomography ImagingJason K Russell, Alexander C Conley, Brian D Boyd, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 28, 2025
Resistance and resilience to Alzheimer's disease in Down syndromeRory Boyle, Elouise A Koops, Beau Ances, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 19, 2026
Sex differences in neuromodulatory subcortical systems and their implications for Alzheimer's diseaseRosaria J Rae, Jessica Marie Hunter Alberhasky, Marion Baillet, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Digital Health|August 17, 2023
Use of focused computerized cognitive training (Neuroflex) to improve symptoms in women with persistent chemotherapy-related cognitive impairmentJennifer N Vega, Paul A Newhouse, Alexander C Conley, et al.
Menopause (New York, N.Y.)|October 28, 2020
Cognitive complaints are associated with smaller right medial temporal gray-matter volume in younger postmenopausal womenAlexander C Conley, Kimberly M Albert, Brian D Boyd, et al.
Research Square|April 16, 2025
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of the Muscarinic M 1 Positive Allosteric Modulator VU0467319 for Alzheimer's disease: A Single Ascending-Dose Study in Healthy ParticipantsAlexander C Conley, Alexandra P Key, Jennifer U Blackford, et al.
Alzheimer'S Research & Therapy|July 2, 2025
Safety, tolerability, pharmacokinetic and pharmacodynamic effects of the muscarinic M<sub>1</sub> positive allosteric modulator VU0467319 for Alzheimer's disease: a single ascending-dose study in healthy participantsAlexander C Conley, Alexandra P Key, Jennifer U Blackford, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 7, 2025
Brain cholinergic terminal density utilizing [<sup>18</sup>F]-fluoroethoxybenzovesamicol PET in adults with Down's syndrome: Relationship to amyloid PET and cognitive performanceJason K Russell, Alexander C Conley, Brian D Boyd, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 24, 2025
BiomarkersJason K Russell, Alexander C Conley, Brian Boyd, et al.
Neurobiology of Aging|February 6, 2025
Differences in cholinergic terminal density in adults with Down syndrome compared to neurotypical controls measured by [<sup>18</sup>F]-fluoroethoxybenzovesamicol positron emission tomography imagingJason K Russell, Alexander C Conley, Brian D Boyd, et al.
Medrxiv : the Preprint Server for Health Sciences|November 22, 2024
Age-Related Changes in the Cholinergic System in Adults with Down Syndrome Assessed Using [<sup>18</sup>F]-Fluoroethoxybenzovesamicol Positron Emission Tomography ImagingJason K Russell, Alexander C Conley, Brian D Boyd, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 28, 2025
Resistance and resilience to Alzheimer's disease in Down syndromeRory Boyle, Elouise A Koops, Beau Ances, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 19, 2026
Sex differences in neuromodulatory subcortical systems and their implications for Alzheimer's diseaseRosaria J Rae, Jessica Marie Hunter Alberhasky, Marion Baillet, et al.
Pageof 3